Rein Therapeutics

Update in progress

RNTX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Rein Therapeutics Inc. is a biopharmaceutical company developing medicines for unmet needs in orphan pulmonary and fibrotic diseases in the United States. Its lead candidate, LTI-03, is a peptide in Phase 2 for idiopathic pulmonary fibrosis. LTI-01, a proenzyme, has completed Phase 1b/2a in loculated pleural effusion. The pipeline includes cystic fibrosis programs and a caveolin-1 peptide for systemic fibrosis, plus LTI-05 in preclinical CF. Formerly Aileron Therapeutics; renamed 2007. Founded 2001; based in Austin, Texas.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive